Stockscreener 앱 받기
4.21
4.10%
-0.18
시간 외 거래:
4.28
0.07
+1.66%
전일 마감가:
$4.39
열려 있는:
$4.38
하루 거래량:
37,978
Relative Volume:
0.72
시가총액:
$5.25M
수익:
$12.99M
순이익/손실:
$-27.83M
주가수익비율:
-0.0207
EPS:
-203.7366
순현금흐름:
$-26.98M
1주 성능:
-11.46%
1개월 성능:
-7.47%
6개월 성능:
-49.03%
1년 성능:
-92.36%
1일 변동 폭
$4.1684
$4.45
1주일 범위
$4.1684
$4.61
52주 변동 폭
$3.6803
$55.26
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.21 | 5.47M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
APVO|Aptevo Therapeutics Inc|Price:4.209|Chg%:-0.181 - TradingKey
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
APVO|Aptevo Therapeutics Inc|Price:4.390|Chg%:+0.020 - TradingKey
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Aptevo Therapeutics Inc. Revenue Breakdown – NASDAQ:APVO - TradingView
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mary Jo Janatpour Net Worth (2026) - GuruFocus
Niowave, Inc. Net Worth (2026) - GuruFocus
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeBPI Reversal - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Aptevo gets $1.5M grant to advance a trispecific cancer drug - Stock Titan
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
Aptevo Therapeutics (APVO) Gains 2.73% as Shares Test Key Resistance Near $4.95Corrective Wave - dars.gov.et
Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView
AP82 Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa
Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan
NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Approach Support at $4.66Volume Climax - dars.gov.et
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics (APVO) Holds Near Support After Modest DeclineHedge Fund Favorites - dars.gov.et
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):